ASX:OCCPharmaceuticals, Biotechnology & Life SciencesBiotechnology
ORTHOCELL ORD
$1.035
+$0.015 (+1.47%)
Day Range
$1.000 - $1.100
52 Week Range
$0.700 - $1.700
Volume
1.04M
Avg Volume (10D)
544.57K
Market Cap
$280.80M
Price Chart
Market Statistics
Open$1.070
Previous Close$1.020
Day High$1.100
Day Low$1.000
52 Week High$1.700
52 Week Low$0.700
Valuation
Market Cap280.80M
Shares Outstanding271.31M
Price to Book7.12
Trading Activity
Volume1.04M
Value Traded1.09M
Bid$1.035 × 2,693
Ask$1.060 × 9,500
Performance
1 Day24.14%
5 Day31.71%
13 Week5.88%
52 Week-25.52%
YTD-0.46%
Technical Indicators
RSI (14)66.94
50-Day SMA$0.866
200-Day SMA$1.089
Latest News
Biotechnology
Orthocell Secures Access to 221 US Military & VA Medical Centres for Remplir
Orthocell wins access to 221 US DoD/VA centres for Remplir, a major US market expansion as HY26 revenue hits A$6.2m and cash sits at A$49.4m.
1 min read
Biotechnology
Orthocell's Remplir Device Used in 23 Ukrainian Soldier Surgeries, Validating Field Utility
Orthocell's Remplir validated after 23 Ukrainian surgeries, boosting defence-market traction and global expansion; HY26 revenue +49%, cash ~A$49m.
1 min read
Biotechnology
Orthocell Appoints Exclusive Remplir Distributor Ahead of UK Rollout
Orthocell names LEDA Orthopaedics exclusive UK distributor for Remplir ahead of regulatory approval, signaling rapid UK rollout and market prep.
1 min read
Biotechnology
Orthocell Reports Accelerated Adoption of Remplir Nerve Repair Technology by Australian Surgeons
Orthocell (ASX: OCC) has confirmed accelerating adoption of lead product Remplir by Australian urologists, with the product so far used in approximately 100 prostate cancer surgeries nationwide to assist in post-surgical complications from peripheral nerve injury.
1 min read